Blood pressure lowering effect of one compound tablet replacement as two tablets of angiotensin 2 receptor blocker(ARB) and calcium channel blocker(CCB)
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Olmesartan medoxomil/azelnidipine (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms ECO
- 27 Jun 2017 Status changed from recruiting to completed.
- 08 Jan 2013 Planned end date (1 Dec 2014) added as reported by University Hospital Medical Information Network - Japan.
- 07 Aug 2012 New trial record